Redeye provides its initial comments on Inhalation Sciences Q4’21 report. With continued high activity in both segments and an order backlog amounting to SEK 5m, we believe that ISAB is on the right track and foresee a gradually increasing commercial activity throughout 2022.

Link to the analysis